CN113046274B - 缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用 - Google Patents
缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用 Download PDFInfo
- Publication number
- CN113046274B CN113046274B CN202110453834.8A CN202110453834A CN113046274B CN 113046274 B CN113046274 B CN 113046274B CN 202110453834 A CN202110453834 A CN 202110453834A CN 113046274 B CN113046274 B CN 113046274B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus reuteri
- capsaicin
- ccfm1175
- group
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title claims abstract description 92
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 78
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 78
- 235000017663 capsaicin Nutrition 0.000 title claims abstract description 40
- 229960002504 capsaicin Drugs 0.000 title claims abstract description 40
- 206010061172 Gastrointestinal injury Diseases 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 abstract description 17
- 102000016938 Catalase Human genes 0.000 abstract description 13
- 108010053835 Catalase Proteins 0.000 abstract description 13
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 13
- 229940118019 malondialdehyde Drugs 0.000 abstract description 13
- 229960003180 glutathione Drugs 0.000 abstract description 11
- 210000002966 serum Anatomy 0.000 abstract description 11
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract description 10
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract description 10
- 238000003304 gavage Methods 0.000 abstract description 10
- 210000001072 colon Anatomy 0.000 abstract description 9
- 230000008595 infiltration Effects 0.000 abstract description 8
- 238000001764 infiltration Methods 0.000 abstract description 8
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 8
- 108010024636 Glutathione Proteins 0.000 abstract description 7
- 235000019617 piquancy Nutrition 0.000 abstract description 7
- 230000006996 mental state Effects 0.000 abstract description 6
- 102000006587 Glutathione peroxidase Human genes 0.000 abstract description 5
- 108700016172 Glutathione peroxidases Proteins 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 4
- 235000021107 fermented food Nutrition 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 239000002068 microbial inoculum Substances 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 42
- 239000000843 powder Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 7
- 101800003906 Substance P Proteins 0.000 description 7
- 102400000096 Substance P Human genes 0.000 description 7
- 239000003223 protective agent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000001630 jejunum Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108090000189 Neuropeptides Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000003405 ileum Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000003797 Neuropeptides Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 229960001305 cysteine hydrochloride Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000002566 Capsicum Nutrition 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229940105657 catalase Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000020122 reconstituted milk Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101000669494 Pelophylax ridibundus Ranakinin Proteins 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035909 sensory irritation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用，属于微生物技术领域。本发明提供了罗伊氏乳杆菌CCFM1175、其组合物、发酵食品、用途及其菌剂制备方法。本发明的罗伊氏乳杆菌CCFM1175能显著改善辣椒素灌胃后小鼠的精神状态，提高灌胃辣椒素后小鼠肝脏的谷胱甘肽过氧化物酶、过氧化氢酶活力和谷胱甘肽含量，降低丙二醛含量，降低灌胃辣椒素后小鼠血清中P物质及降钙素基因相关肽的水平，改善辣椒素导致的小肠绒毛脱落、结肠炎症细胞浸润等组织损伤。本发明的罗伊氏乳杆菌CCFM1175用于制备解辣、护肠胃的药物组合物与发酵食品，具有非常广泛的应用前景。
Description
技术领域
本发明涉及缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用，属于微生物技术领域。
背景技术
辣椒素是辣椒的主要成分，具有镇痛、抗氧化、抗肥胖、抑菌等功能活性，被广泛应用于饮食及药理。但辣椒素具有强刺激性，因此日常生活中食用辣椒后常产生灼热感、烧心、腹痛等不良感知，主要机理为辣椒素与TRPV1受体结合，诱导疼痛介质如神经肽的传递及下游促炎因子的释放，从而造成胃肠损伤。
生活中常见的“解辣”物质有醋、牛奶等，其中醋中的醋酸能与辣椒素发生酸碱中和反应，而牛奶中的脂溶性物质包裹辣椒素由口腔进入消化道，从而减轻了“辣”的感官刺激。但以上解辣机理都基于辣椒素的脂溶性性质，无法缓解辣椒素引起的胃肠道损伤。
鉴于现有解辣方法存在的多种问题，替代传统食品的缓解解辣、护肠胃的新方案显得尤为重要。研究发现，部分益生菌可与辣椒素受体TRPV1相互作用，但与辣椒素致胃肠损伤的关系不明确。因此，市面上也缺少缓解辣椒素致胃肠损伤的益生菌制剂或发酵制品，寻找具有解辣功能的益生菌，以促使其在日常食辣人群中的搭配应用。
发明内容
本发明的目的是提供一株罗伊氏乳杆菌(Lactobacillus reuteri)CCFM1175，已于2021年3月19日保藏于广东省微生物菌种保藏中心，保藏编号为GDMCC No：61572。
在一种实施方式中，所述罗伊氏乳杆菌CCFM1175具有如下特性：
(1)其微生物形态学特征为：细胞呈轻微不规则，单个或成短链，无鞭毛，无孢子。
(2)培养性状：在MRS培养基上培养48h后的菌落一般呈乳白色，光滑凸起，乳白色、直径为1-2mm。
本发明还提供了含所述罗伊氏乳杆菌的组合物。
在一种实施方式中，所述组合物中，罗伊氏乳杆菌的含量≥1×105CFU/g或1×105CFU/mL。
在一种实施方式中，所述组合物为发酵剂，所述发酵剂是利用含有所述罗伊氏乳杆菌的菌液制备所得到的粉剂，含有1011CFU/g以上活的罗伊氏乳杆菌。
在一种实施方式中，所述粉剂是将含有所述活性罗伊氏乳杆菌的菌液通过常规冷冻干燥工艺或其它工艺制备所得到的。
在一种实施方式中，所述冻干保护剂成分为80～120g/L脱脂乳粉、80～140g/L海藻糖、140-180g/L蔗糖和水。
在一种实施方式中，所述的发酵剂是通过下述制备步骤得到的：
(1)培养基的制备：蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、半胱氨酸氨酸盐0.5g/L，pH为6.8。
(2)保护剂的制备：使用水与保护剂原料混合制备得到含有130g/L脱脂奶粉、20g/L蔗糖、20g/L海藻糖的保护剂；
(3)将罗伊氏乳杆菌CCFM1175接种至步骤(1)所述培养基中，在37℃培养18h，离心收集菌体，用pH＝7.2磷酸盐缓冲液清洗菌体2～4次，用步骤(2)所述的保护剂重悬达到浓度1010CFU/mL，进行冷冻干燥，得到所述的发酵剂。
在一种实施方式中，所述冻干保护剂的成分包括脱脂乳粉、海藻糖、蔗糖和水。
在一种实施方式中，所述冻干保护剂在重悬液中的添加量为菌泥总重量的2～4倍。
本发明的第二个目的是提供所述罗伊氏乳杆菌在制备缓解辣椒素诱发的胃肠损伤中的应用。
在一种实施方式中，所述应用包括如下至少一种功能：
(1)改善哺乳动物精神状态；
(2)提高哺乳动物肝脏谷胱甘肽过氧化物酶活力、过氧化氢酶活力和谷胱甘肽含量，降低丙二醛含量；
(3)降低哺乳动物血清中P物质及降钙素基因相关肽水平；
(4)改善哺乳动物空、回肠绒毛脱落、隐窝增生、结肠炎症细胞浸润等损伤。
在一种实施方式中，所述产品中含有罗伊氏乳杆菌CCFM1175活菌。
在一种实施方式中，所述产品中，罗伊氏乳杆菌CCFM1175的活菌数为不低于1×108CFU/mL。
在一种实施方式中，所述产品为药品，所述药品含有罗伊氏乳杆菌、药物载体和/或药用辅料。
在一种实施方式中，所述药物载体包含微囊、微球、纳米粒以及脂质体。
在一种实施方式中，所述药用辅料包含赋形剂以及附加剂。
在一种实施方式中，所述药用辅料包含抗黏合剂、渗透促进剂、缓冲剂、增塑剂、表面活性剂、消泡剂、增稠剂、包合剂、吸收剂、保湿剂、溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、pH值调节剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、整合剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、发泡剂、助悬剂、包衣材料、芳香剂、稀释剂、絮凝剂与反絮凝剂、助滤剂以及释放阻滞剂。
在一种实施方式中，所述附加剂包含微晶纤维素、羟丙基甲基纤维素以及精制卵磷脂。
在一种实施方式中，所述药品的剂型包含颗粒剂、胶囊剂、片剂、丸剂或口服液。
在一种实施方式中，所述产品包含食品、药品或保健食品。
在一种实施方式中，所述食品包含使用含有罗伊氏乳杆菌的发酵剂生产得到的乳制品、豆制品或果蔬制品。
有益效果：本发明提供的罗伊氏乳杆菌CCFM1175能显著改善辣椒素灌胃后小鼠的精神状态；提高灌胃辣椒素后小鼠肝脏的谷胱甘肽过氧化物酶、过氧化氢酶活力和谷胱甘肽含量，降低丙二醛含量；能够降低灌胃辣椒素后小鼠血清中P物质及降钙素基因相关肽的水平；能够改善辣椒素导致的小肠绒毛脱落、结肠炎症细胞浸润等组织损伤。可用于制备解辣、护肠胃的药物组合物、发酵食品或发酵饮品，具有非常广泛的应用前景。
生物材料保藏
罗伊氏乳杆菌(Lactobacillus reuteri)CCFM1175，分类命名为Lactobacillusreuteri，已于2021年3月19日保藏于广东省微生物菌种保藏中心，保藏编号为GDMCC No：61572。
附图说明
图1是不同组别小鼠灌胃后的精神状态。
图2是不同组别小鼠肝脏的谷胱甘肽过氧化物酶活力。
图3是不同组别小鼠肝脏的过氧化氢酶活力。
图4是不同组别小鼠肝脏的谷胱甘肽含量。
图5是不同组别小鼠肝脏的丙二醛含量。
图6是不同组别小鼠血清中的P物质含量。
图7是不同组别小鼠血清中的降钙素基因相关肽含量。
图8是不同组别小鼠的空肠组织形态(HE染色)。
图9是不同组别小鼠的回肠组织形态(HE染色)。
图10是不同组别小鼠的结肠组织形态(HE染色)。
具体实施方式
下述实施例中所述实验方法，如无特殊说明，均为常规方法；所述试剂和生物材料，如无特殊说明，均可从商业途径获得。
下述实施例中涉及的培养基如下：
MRS固体培养基(g/L)：蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、琼脂20g/L、半胱氨酸氨酸盐0.5g/L，pH＝6.8。
MRS液体培养基(g/L)：蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温80 1mL/L、半胱氨酸氨酸盐0.5g/L，pH＝6.8。
实施例1：罗伊氏乳杆菌的筛选及鉴定
1、筛选
以来源于河南夏邑的人群粪便为样本，将样本经预处理后，在30％甘油中保存于-80℃冰箱，取出解冻后，混匀样本吸取0.5mL样本加到4.5mL 0.9％生理盐水进行梯度稀释，选择合适的梯度稀释液涂布在MRS固体培养基上，于37℃培养48h，挑取典型菌落至MRS平板上划线纯化，挑取单菌落转接至液体MRS液体培养基增菌，30％甘油保藏，得到菌株CCFM1175。
2、鉴定
提取菌株CCFM1175的全基因组DNA进行16S rDNA扩增，收集扩增后的DNA片段用于测序，将该序列在NCBI中进行核苷酸序列比对和进化树分析，结果显示菌株为罗伊氏乳杆菌，命名为罗伊氏乳杆菌(Lactobacillus reuteri)CCFM1175。
实施例2：罗伊氏乳杆菌的培养
将罗伊氏乳杆菌(Lactobacillus reuteri)接入MRS固体培养基中于37℃培养48h后，观察其菌落并在显微镜下对其菌体进行观察，发现其菌落乳白色、不规则型、圆形凸起、光滑，其菌体形状呈轻微不规则、圆形末端的弯曲杆菌，通常单个、成对和小簇存在。
将罗伊氏乳杆菌(Lactobacillus reuteri)接入MRS液体培养基中于37℃培养18h后，转入新鲜的MRS液体培养基中，同样条件培养18h，6000rpm离心菌体8min，0.9％生理盐水洗涤菌体后6000rpm再次离心5min，得到菌体，用30％蔗糖溶液重悬至菌浓度为1011CFU/mL，冻存于80℃待用。
实施例3：罗伊氏乳杆菌对辣椒素致胃肠损伤小鼠精神状态的影响
取SPF级6周龄雄性C57BL/6小鼠30只饲养于恒温恒湿的动物房内，严格遵循12h白昼和12h黑夜的循环标准，标准配方商业化饲料喂养，自由进水。适应性喂养7天后，随机分为3组，每组10只，3组分别为：对照组、辣椒素组、CCFM1175组、FHNXY12L7组、DSM17938组。
第8-21天为14天灌胃干预期，每次灌胃剂量均为0.2mL/只，每天灌胃时间保持一致。其中对照组和辣椒素组灌胃生理盐水，CCFM1175组灌胃罗伊氏乳杆菌CCFM1175(109CFU/只)，FHNXY12L7组灌胃罗伊氏乳杆菌FHNXY12L7(109CFU/只)，DSM17938组灌胃罗伊氏乳杆菌DSM17938(109CFU/只)，其中FHNXY12L7是和CCFM1175同批筛选出来的另一株罗伊氏乳杆菌。DSM17938是一株广泛使用的商业化罗伊氏乳杆菌，已公开于公开号为“CN104244736A”，发明名称为“用于肠神经***发育的罗伊氏乳杆菌DSM17938”的专利申请文件中。
在干预期的最后7天，即第15-21天，进行辣椒素造模。在灌胃生理盐水/菌悬液两小时后，辣椒素组、CCFM1175组、FHNXY12L7组、DSM17938组灌胃60mg/kg·bw辣椒素溶液(溶剂：3％乙醇+10％吐温80+87％生理食盐水，v/v)，对照组灌胃辣椒素溶液的溶剂。
在灌胃期间，记录灌胃后小鼠的精神状态，如图1所示。通过对小鼠精神状态的观察发现，与对照组小鼠相比，辣椒素组小鼠灌胃辣椒素后出现刨坑、埋头现象，2-3分钟后呈卧趴状，且呼吸急促，甚至出现部分小鼠死亡的现象，推测可能与辣椒素对口腔的感官刺激性有关。FHNXY12L7组、DSM17938组小鼠灌胃后呈卧趴状，且呼吸急促，但CCFM1175组小鼠在灌胃过程中均未出现以上状态，推测该菌株可能缓解了辣椒素对消化道的强刺激性，且缓解作用优于罗伊氏乳杆菌FHNXY12L7和DSM17938。
实施例4：罗伊氏乳杆菌对辣椒素致胃肠损伤小鼠肝脏氧化应激的影响
生物体内存在氧化应激损伤的防御机制，当机体受到刺激时会调控下游抗氧化酶，如谷胱甘肽过氧化物酶(GSH-Px)、过氧化氢酶(CAT)等的表达，进而抑制炎症、凋亡反应，发挥保护细胞的作用。谷胱甘肽(GSH)是机体内最重要的非酶性抗氧化物，该物质的减少会导致线粒体功能损伤，进一步导致活性氧自由基的过量增加，从而引起氧化损伤。而MDA被认为是机体脂质过氧化的重要产物和指示物，丙二醛(MDA)含量的变化反映了机体氧化损伤的程度。
动物模型的建立方法同实施例3，对灌胃结束的小鼠禁食12小时后，麻醉小鼠并迅速摘眼球取血，辅以颈椎脱臼法处死。对处死后小鼠进行解剖，用剪刀在腹正中线稍左侧剪开一个小口，向前至胸骨间突处，再沿肋骨后缘向两侧做横切口，暴露腹腔。观察腹腔内器官正常位置，摘取肝脏，加入9倍组织块重量的预冷的生理盐水充分研磨，使组织匀浆化，4℃下6000rpm离心15分钟，收集上清即为组织匀浆液，采用南京建成试剂盒测定各组小鼠肝匀浆中GSH-Px、CAT、GSH和MDA含量。
各组小鼠肝匀浆中GSH-Px、CAT、GSH和MDA含量检测结果如图2-图5。
如图2所示，与对照组相比，辣椒素组小鼠肝脏GSH-Px活力显著下降22.5％，而罗伊氏乳杆菌干预组小鼠CCFM1175组、FHNXY12L7组、DSM17938组分别下降5.2％、19.8％、17.3％。表明辣椒素灌胃导致小鼠肝脏抗氧化酶GSH-Px活力下降，罗伊氏乳杆菌CCFM1175可有效改善该损伤，罗伊氏乳杆菌FHNXY12L7及DSM17938并无显著改善作用。如图3所示，各组小鼠的肝脏CAT活力也显示出相似的结果，辣椒素组小鼠的CAT活力较对照组降低了32.5％，CCFM1175组小鼠的CAT活力与对照组小鼠无显著性差异，FHXY12L7组及DSM17938组小鼠的CAT酶活较对照组分别下降21.4％和24.9％。
比较小鼠肝脏谷胱甘肽含量可知(图4)，辣椒素组、CCFM1175组、FHNXY12L7组及DSM17938组小鼠肝脏的谷胱甘肽含量较对照组(8.45±1.52μmol/mg蛋白)分别降低64.0％，14.8％、50.2％、33.2％。而氧化损伤标志物MDA的含量在各处理组中分别为：对照组＝0.44±0.07nmol/mg蛋白，辣椒素组＝0.67±0.10nmol/mg蛋白，CCFM1175组＝0.47±0.10nmol/mg蛋白，FHNXY12L7组＝0.79±0.07nmol/mg蛋白，DSM17938组＝0.51±0.06nmol/mg蛋白。其中灌胃罗伊氏乳杆菌CCFM1175及罗伊氏乳杆菌DSM17938后，小鼠肝脏MDA含量与对照组无显著性差异，而辣椒素组及罗伊氏乳杆菌FHNXY12L7组小鼠MDA含量显著增加(图5)。
上述结果表明，灌胃罗伊氏乳杆菌CCFM1175能有效缓解辣椒素导致的肝脏氧化损伤，具体表现为恢复了GSH-PX、CAT的活性和GSH的水平，有效降低了组织中MDA含量，且缓解效果显著高于罗伊氏乳杆菌FHNXY12L7及罗伊氏乳杆菌DSM17938。
实施例5：罗伊氏乳杆菌对辣椒素致胃肠损伤小鼠血清神经肽的影响
胃肠道中的辣椒素受体TRPV1可通过调节神经肽的释放来介导神经***与免疫***之间的串扰，其中P物质(SP)、降钙素基因相关肽(CGRP)两种神经肽参与伤害感受的传递，在疼痛和炎症反应中起重要作用。
动物模型的建立方法同实施例3，区别在于，对灌胃结束的小鼠禁食12小时后，麻醉小鼠并迅速摘眼球取血，辅以颈椎脱臼法处死。收集处死后小鼠的血液样本，将血液样本于室温静置3h，4000rpm离心15min，小心收集上层血清，按照上海酶联试剂盒说明书测定小鼠血清中的SP及CGRP含量。
如图6、7所示，辣椒素组小鼠血清中神经肽SP及CGRP含量相对对照组分别增加35.8％、47.4％，表明小鼠受到辣椒素刺激后可促神经肽类物质释放，从而增加痛感传递。而灌胃罗伊氏乳杆菌CCFM1175后，与辣椒素组小鼠相比，血清中SP、CGRP水平有所降低，较对照组仅增加9.7％、5.2％，表明灌胃罗伊氏乳杆菌CCFM1175能够缓解辣椒素导致的内脏痛觉过敏。FHNXY12L7组及DSM17938组小鼠血清中SP水平较对照组分别增加37.4％、22.2％，CGRP水平较对照组分别增加38.4％、23.9％，表明上述两株罗伊氏乳杆菌无法缓解辣椒素导致的内脏痛觉过敏。
实施例6：罗伊氏乳杆菌对辣椒素致胃肠损伤小鼠胃肠组织形态的影响
动物模型的建立方法同实施例3，区别在于，对灌胃结束的小鼠禁食12小时后，麻醉小鼠并迅速摘眼球取血，辅以颈椎脱臼法处死。对处死后小鼠进行解剖，用剪刀在腹正中线稍左侧剪开一个小口，向前至胸骨间突处，再沿肋骨后缘向两侧做横切口，暴露腹腔。观察腹腔内器官正常位置，摘取空肠、回肠和结肠，生理盐水轻微漂洗后置于4％多聚甲醛固定液中固定。固定48h后进行石蜡包埋、切片，采用苏木精-伊红染色(HE)观察空肠、回肠和结肠组织形态。
如图8所示，对照组空肠绒毛结构完整，排列整齐。辣椒素组、FHNXY12L7组及DSM17938组绒毛排列不规则，并伴随局部绒毛破损、脱落，出现隐窝增生的现象，但未有大量炎性细胞浸润。而罗伊氏乳杆菌CCFM1175组空肠绒毛结构及形态均有一定程度恢复。
如图9所示，辣椒素组回肠绒毛排列不规则，大量绒毛破损、脱落，出现隐窝增生的现象，FHNXY12L7组及DSM17938组绒毛脱落，但未有隐窝增生。CCFM1175组回肠绒毛结构完整，同对照组类似。
如图10所示，对照组小鼠的结肠结构完整，粘膜及绒毛排列整齐，具有健康的隐窝结构，且富含杯状细胞，没有炎症细胞浸润或粘膜损伤。辣椒素组及FHNXY12L7组小鼠出现少量炎症细胞浸润，DSM17938组小鼠的姐肠组织杯状细胞大量减少，而CCFM1175组小鼠的结肠组织细胞形态同对照组相似，富含杯状细胞，未出现炎性细胞浸润及黏膜损伤。
综合不同处理组小鼠空肠、回肠及结肠组织形态结果，我们发现摄入60mg/kg/day辣椒素将导致小鼠空肠及回肠绒毛掉落，出现隐窝增生现象，同时结肠出现炎性细胞浸润及杯状细胞减少，一定程度上造成了小鼠的胃肠损伤。灌胃罗伊氏乳杆菌CCFM1175可显著改善这种损伤，且改善程度显著高于罗伊氏乳杆菌FHNXY12L7及罗伊氏乳杆菌DSM17938。
实施例7：罗伊氏乳杆菌CCFM1175用于制备即食性乳酸菌粉剂
培养基的制备：蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠2g/L、酵母粉5g/L、柠檬酸氢二铵2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、吐温801mL/L、半胱氨酸氨酸盐0.5g/L，pH＝6.8。
保护剂的制备：配制含有130g/L脱脂奶粉、20g/L蔗糖、20g/L海藻糖的保护剂溶液。
菌粉的具体制备过程如下：
将罗伊氏乳杆菌CCFM1175按2％接种量(按体积计)接种到所述培养基中，然后在温度37℃的条件下培养18h，用pH＝7.2磷酸盐缓冲液清洗2～4次，用保护剂重悬达到浓度1010CFU/mL，进行冷冻干燥得到所述即食性乳酸菌粉剂。该粉剂也可作为发酵剂。
可选地，菌粉的制备过程中，可与其他种、属的乳酸菌混合，制备获得混合菌液，再进行冷冻干燥。
实施例8：罗伊氏乳杆菌CCFM1175用于制备发酵乳
发酵乳的具体制备过程如下：
将牛乳或复原乳在95℃热杀菌20min，然后冷却至37℃，再加入罗伊氏乳杆菌CCFM1175或实施例7制备的含罗伊氏乳杆菌CCFM1175的发酵剂，使菌体浓度达到107CFU/mL以上，并加入适量市售发酵剂(含有嗜热链球菌、保加利亚乳杆菌)，使接种后的总活菌数达到104～105CFU/mL，其中，市售发酵剂中嗜热链球菌与保加利亚乳杆菌的数量比为1：(1～2)。将接种后的牛乳或复原乳在37℃发酵24h后，于4℃冷藏12h即得到含罗伊氏乳杆菌活菌的发酵乳。
虽然本发明已以较佳实施例公开如上，但其并非用以限定本发明，任何熟悉此技术的人，在不脱离本发明的精神和范围内，都可做各种的改动与修饰，因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (10)
1.罗伊氏乳杆菌（Lactobacillus reuteri）CCFM1175，已于2021年3月19日保藏于广东省微生物菌种保藏中心，保藏编号为GDMCC No：61572。
2.含权利要求1所述罗伊氏乳杆菌CCFM1175的组合物。
3.根据权利要求2所述的组合物，其特征在于，所述组合物中罗伊氏乳杆菌的含量≥1×105 CFU/g或1×105CFU/mL。
4.含权利要求1所述罗伊氏乳杆菌CCFM1175的发酵剂，其特征在于，含有≥1011CFU/g活的罗伊氏乳杆菌CCFM1175。
5.根据权利要求4所述的发酵剂，其特征在于，是将含罗伊氏乳杆菌CCFM1175的菌液冷冻干燥制备得到的。
6.一种发酵制品，其特征在于，所述发酵制品是使用权利要求1所述的罗伊氏乳杆菌，或权利要求4~5任一所述的发酵剂生产得到的发酵食品。
7.一种发酵制品，其特征在于，所述发酵制品是使用权利要求1所述的罗伊氏乳杆菌，或权利要求4~5任一所述的发酵剂生产得到的发酵饮品。
8.权利要求1所述的罗伊氏乳杆菌CCFM1175在制备预防和/或缓解辣椒素诱发的胃肠损伤的药物中的应用。
9.根据权利要求8所述的应用，其特征在于，所述药物含有罗伊氏乳杆菌CCFM1175、药物载体和/或药用辅料。
10.含有权利要求1所述罗伊氏乳杆菌CCFM1175的乳制品、豆制品或果蔬制品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110453834.8A CN113046274B (zh) | 2021-04-26 | 2021-04-26 | 缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110453834.8A CN113046274B (zh) | 2021-04-26 | 2021-04-26 | 缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113046274A CN113046274A (zh) | 2021-06-29 |
| CN113046274B true CN113046274B (zh) | 2022-09-27 |
Family
ID=76520621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110453834.8A Active CN113046274B (zh) | 2021-04-26 | 2021-04-26 | 缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113046274B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112538441A (zh) * | 2020-10-30 | 2021-03-23 | 江南大学 | 缓解etec所致腹泻的罗伊氏乳杆菌ccfm1144及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301983B2 (en) * | 2014-03-07 | 2016-04-05 | Genmont Biotech Inc. | Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
| EP3212001A4 (en) * | 2014-10-31 | 2018-04-25 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| CN111543639A (zh) * | 2019-02-11 | 2020-08-18 | 丰华生物科技股份有限公司 | 用以保护肝脏的含乳酸菌菌株的食品组合物以及医药组合物 |
| US20200330530A1 (en) * | 2019-04-19 | 2020-10-22 | Glac Biotech Co., Ltd. | Hepatoprotection food composition and pharmaceutical composition with strains of lactic acid bacteria |
| CN112458027B (zh) * | 2020-12-16 | 2022-08-02 | 江南大学 | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 |
-
2021
- 2021-04-26 CN CN202110453834.8A patent/CN113046274B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112538441A (zh) * | 2020-10-30 | 2021-03-23 | 江南大学 | 缓解etec所致腹泻的罗伊氏乳杆菌ccfm1144及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113046274A (zh) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4881304B2 (ja) | 新規ビフィドバクテリウム属細菌及びその利用 | |
| US9649347B2 (en) | Protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| KR101618391B1 (ko) | 높은 옥살산 분해능을 갖는 유산균 | |
| US20140363501A1 (en) | The protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
| CZ300143B6 (cs) | Kmen Lactobacillus, jeho použití a výrobek jej obsahující | |
| JP5046684B2 (ja) | 腸管バリア機能の機能回復剤及び腸管バリア透過性の亢進阻害剤 | |
| CN113122478B (zh) | 一株能够缓解辣椒素致胃肠损伤的副干酪乳杆菌及其用途 | |
| CN111996153B (zh) | 一种短双歧杆菌及其应用 | |
| CN109929779A (zh) | 一种含有生物活性肽的益生菌制剂及其制备方法和应用 | |
| WO2008004794A1 (en) | New functional fermented milk (yogurt) for use in dieting | |
| JP6894097B2 (ja) | 腎性貧血改善用組成物 | |
| CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
| CN112029674A (zh) | 改善肠道微生态缓解便秘的凝结芽孢杆菌bc01及应用 | |
| JP3648233B2 (ja) | 飼料組成物 | |
| CN114107134B (zh) | 一株侧孢短芽孢杆菌及其应用 | |
| JP5254682B2 (ja) | 経口摂取用皮膚性状改善剤 | |
| CN110835615B (zh) | 乳双歧杆菌gkk2的活性物质、含其的组合物及其促进长寿的用途 | |
| TW202108756A (zh) | 鼠李糖乳桿菌gklc1、組合物及其改善酒精性肝損傷、胃損傷及/或腸損傷之用途 | |
| CN111035661A (zh) | 植物乳杆菌的用途 | |
| JPH07265064A (ja) | 腸内細菌叢改善組成物 | |
| CN113046274B (zh) | 缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用 | |
| TWI829090B (zh) | 抗憂鬱劑、抗老化劑及抗肥胖劑 | |
| ES2965365T3 (es) | Cepa bacteriana y el uso de la misma | |
| KR102246957B1 (ko) | 장내 세균총에 유익한 효능을 가진 유산균을 활용한 면역력 향상 기능성 첨가물 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |